ROLLING MEADOWS, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) — RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”) (formerly known as Agrify Corporation), which delivers well-being to consumers through its portfolio of iconic licensed brands and hemp-derived THC products including Señorita THC Margaritas and RYTHM, today announced financial results for the quarter ended September 30, 2025.  Third Quarter 2025 Financial ResultsRevenue from continuing operations of $4.0 million, up 98% from $2.0 million in the prior quarter. $8.9 million operating loss from continuing operations. Cash balance of $35.6 million. Approximately 2.0 million shares, 7.6 million warrants outstanding and 6.2 million shares issuable upon conversion of outstanding convertible notes (excluding interest) as of September 30, 2025.Recent DevelopmentsThe Company’s...

All amounts in U.S. dollars unless otherwise stated TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Onex Corporation (TSX: ONEX) today announced its financial results for the third quarter ended September 30, 2025. “Onex’ third quarter results reflect ongoing progress across the business,” said Bobby Le Blanc, CEO and President. “Our Private Equity teams continue to return meaningful capital to investors through strategic realizations, while planting the seeds for future growth through new investments. Our Credit team had another strong quarter bringing total capital raised or extended this year to more than $10 billion.”Financial Results (unaudited)($ millions except per share amounts) Three Months Ended Sept. 30 Nine Months Ended Sept. 30    2025 2024 2025 2024  Net earnings $ 39 $ 127 $ 436 $ 305  Net earnings per diluted...

Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce its financial and operational results for the third quarter ending September 30, 2025. The Company remains in a strong financial position. A quarter-over-quarter comparison of Q3 2025 with Q2 2025 highlights a period of significant strengthening, with a 275% increase in shareholder equity, an 86% reduction in the debt-to-equity ratio, a 50% decrease in total liabilities, primarily due to the elimination of all liabilities associated with the previously issued convertible debentures, and an 8% reduction...

Financial Overview – Third QuarterRevenues of $165 Million, Down 41% From a Record a Year Ago Adjusted Pre-Tax Income of $20 Million, GAAP Pre-Tax Income of $12 Million Adjusted EPS of $0.13; GAAP Diluted EPS of $0.08Financial Overview – Nine MonthsRevenues of $532 Million, Down 18% From a Record a Year Ago Adjusted Pre-Tax Income of $53 Million, GAAP Pre-Tax Income of $30 Million Adjusted EPS of $0.51; GAAP Diluted EPS of $0.37Talent InvestmentYear-to-Date Added Twelve Partners and Nine Managing Directors Two Additional Partners and Two Additional Managing Directors to Join Firm in Coming Months Closed Acquisition of Devon Park AdvisorsCapital ManagementStrong Balance Sheet with $186 Million of Cash and No Debt Year-to-Date Retired More Than Six Million Shares and Share Equivalents through Purchase, Exchange...

Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjusted non-GAAP EBITDA of $59.6 million, an increase of 69.8% year-over-year Diluted GAAP income per share of $1.13 and record adjusted non-GAAP diluted earnings per share of $2.04 Raised 2025 total net revenue guidance to $854.0 million to $873.0 million, adjusted non-GAAP EBITDA to $221.0 million to $228.0 million, and adjusted non-GAAP diluted earnings per share of $7.37 to $7.64 Rare Disease net revenues expected to represent approximately 50% of total Company net revenues in 2025, including revised guidance for:Purified Cortrophin Gel net revenues of $347.0 million to $352.0 million, representing year-over-year growth of 75% to 78%, and ILUVIEN(1)...

VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) announces its financial and operating results for the three and nine months ended September 30, 2025. All dollar amounts are in US dollars ($). “Endeavour Silver delivered a strong third quarter, highlighted by a significant increase in production and robust revenue growth,” commented Dan Dickson, Chief Executive Officer. “With silver equivalent production up 88% year-over-year and operating cash flow more than doubling, we continue to demonstrate the strength of our mining operations and our team’s commitment to operational excellence. With the recent achievement of commercial production at Terronera in October, we are excited about the Company’s future growth and the combined performance of...

Castellum, Inc. Reports Breakthrough Q3 2025 Results with First-Ever Positive Net IncomeCastellum, Inc. (NYSE-American: CTM) (“Castellum” or the “Company”), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces its financial results for the third quarter ended September 30, 2025, featuring its first ever quarterly GAAP net income, improved operating performance, record cash, and as previously reported, further debt reduction – www.castellumus.comVIENNA, Va., Nov. 07, 2025 (GLOBE NEWSWIRE) — Castellum, Inc. (NYSE-American: CTM) (“Castellum” or the “Company”), a cybersecurity, electronic warfare, and software services company focused on the federal government, announces its financial results for the third quarter...

Q3 2025 revenues were $11.5 million, up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9%, versus 75.5% in Q3 2024. GAAP Operating Income was $1.5 million for Q3 2025 versus $2.0 million in Q3 2024. Q3 2025 included stock-based compensation costs of $1.4 million versus $0 in Q3 2024. Company provides guidance for revenues of $13-$14 million for Q4 2025. EDEN PRAIRIE, Minn., Nov. 07, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to provide its financial results for the three months ended September 30, 2025. Quarter ended September 30, 2025Revenue for the three months ended September 30, 2025, totaled...

TULIKIVI CORPORATION  INTERIM REPORT  7 NOV 2025 AT 1 PM – The Tulikivi Group’s net sales were EUR 7.0 million (EUR 7.2 million, 7–9/2024) in the third quarter and EUR 21.6 million (EUR 25.0 million, 1–9/2024) in the review period.– The Tulikivi Group’s operating profit was EUR 0.2 (0.5) million in the third quarter and EUR 0.0 (1.6) million in the review period.– The Tulikivi Group’s profit before taxes was EUR 0.0 million (0.3 million) in the third quarter and EUR -0.6 (1.0) million in the review period.– The equity ratio at the end of the review period was 48.6 per cent (50.9).– Order books stood at EUR 3.1 (3.1) million at the end of the review period.– The Suomussalmi talc project made good progress.– Future outlook: Net sales in 2025 are expected to be EUR 29 to 33 million and the comparable...

Reports third quarter 2025 total revenue of $7.8 million, representing 3% growth compared to the third quarter of 2024.Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, increased 32% compared to the third quarter of 2024 driven by record consumable revenue.Reports third quarter gross margin of 9%, representing a 70-basis point improvement compared to the third quarter of 2024. Announces record multi-system order from an existing Top 20 global biopharma customer to automate global manufacturing network. Raises full year 2025 total revenue guidance to at least $33.0 million, which assumes at least 27 Growth Direct system placements.LEXINGTON, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology...